

1635



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/006,430	
	Filing Date	December 10, 2001	
	First Named Inventor	Mark J. Graham	
	Group Art Unit	1635	
	Examiner Name	McGarry, Sean	
Total Number of Pages in This Submission	5	Attorney Docket Number	ISIS0072-100

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) <div>Remarks</div>	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): References AR-AX International Search Report Dated August 27, 2003

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Gwilym Attwell Reg No.: 45,449
Signature	
Date	September 30, 2003

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: September 30, 2003			
Typed or printed name	Gwilym Attwell	Reg No.: 45,449	
Signature		Date	September 30, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



ISIS0072-100

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mark J. Graham, et al. : Art Unit:1635
Serial No.: 10/006,430 : Examiner: Sean McGarry
Filed: December 10, 2001 :
For: ANTISENSE MODULATION OF :
CD81 EXPRESSION

CERTIFICATION IN ACCORDANCE WITH 37 C.F.R. §1.97(e)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


S I R :

Pursuant to 37 C.F.R. §§ 1.97(e), Applicants assert:

☒ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) not more than three months prior to the filing of the information disclosure statement.

Respectfully submitted,



Gwilym Attwell
Registration No.: 45,449
Attorney for Applicant

Enclosures:
PTO/SB/08A

Dated: September 30, 2003

Cozen O'Connor
1900 Market Street
Philadelphia, PA 19103
Tel: 215-665-2000



ISIS0072-100


PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mark J. Graham, et al : Art Unit:1635
Serial No.: 10/006,430 : Examiner: Sean McGarry
Filed: December 10, 2001 :
For: ANTISENSE MODULATION OF :
CD81 EXPRESSION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

DATE OF DEPOSIT: September 30, 2003
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID
ON THE DATE INDICATED ABOVE AND IS ADDRESSED
TO THE ASSISTANT COMMISSIONER FOR PATENTS,
BOX 1450, ALEXANDRIA, VA 22313-1450


Gwilym Atwell
REGISTRATION NO:45,449

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


S I R :

Pursuant to 37 C.F.R. § 1.56 and in accordance with §§ 1.97-1.98,
information relating to the above-identified application is hereby disclosed on the
attached PTO/SB/08A. Inclusion of information in this statement is not to be construed
as an admission that this information is material as that term is defined in 37 C.F.R. §
1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information
Disclosure Statement shall not be construed to mean that a search has been made.

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore a Certification in Accordance with §1.97(e) accompanies this transmittal

Respectfully submitted,



Gwilym Attwell
Registration No. 45,449
Attorney for Applicant

Enclosures:
PTO/SB/08A

Dated: September 30, 2003

Cozen O'Connor
1900 Market Street
Philadelphia, PA 19103
Tel: 215-665-2000

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of

2

Complete if Known

Application Number	10/006,430
Filing Date	December 10, 2001
First Named Inventor	Mark J. Graham
Group Art Unit	1635
Examiner Name	McGarry, Sean
Attorney Docket Number	ISIS0072-100

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AT	AGRAWAL, S. ANTISENSE OLIGONUCLEOTIDES; TOWARDS CLINICAL TRIALS, TIBTECH, OCTOBER, 1996, VOL. 14 PP. 376-387	
	AU	BENNETT ET AL., PHARMACOLOGY OF ANTISENSE THERAPEUTIC AGENTS. METHODS IN MOLECULAR MEDICINE; ANTISENSE THERAPEUTICS, 1996, PAGES 13-46	
	AV	BRANCH, A.D. A GOOD ANTISENSE MOLECULE IS HARD TO FIND. TIBS 23, FEBRUARY, 1998 PP. 45-50	
	AW	JEN ET AL., SUPPRESSION OF GENE EXPRESSION BY TARGETED DISRUPTION OF MESSENGER RNA; AVAILABLE OPTIONS AND CURRENT STRATEGIES, STEM CELLS, 2000, 18, PAGES 307-319	
	AX	INTERNATIONAL SEARCH REPORT DATED AUGUST 27, 2003	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.